Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Analysis on the association between PPARα/γ polymorphisms and lipoprotein(a) in a Chinese Han population


Lipoprotein(a) [Lp(a)], a low-density lipoprotein-like particle, is recognized as an independent risk factor for atherosclerosis, cardiovascular diseases, and diabetic vascular diseases. Our recent studies revealed that the single nucleotide polymorphisms (SNPs) of peroxisome proliferator-activated receptors (PPARα/δ/γ) gene are involved in the regulation of lipid storage and metabolism. In order to investigate the relationships between the SNPs of PPARα/γ gene and plasma levels of Lp(a), 644 participants were randomly selected from Chinese Han population in the present study. As the results shown, Lp(a) was significantly associated with L162V (rs1800206) in PPARα. Compared with those subjects with widetype (LL), significantly higher Lp(a) concentration was determined in the individuals with mutant (LV + VV) (mean difference: 49.07 mg/l, 95 % CI 23.32–74.82 mg/l, p = 0.0002). Moreover, with generalized multifactor dimensionality reduction analysis, our present results indicated that there was a significant association between plasma Lp(a) level and gene–gene interaction among the polymorphisms rs1800206, rs135539 in PPARα and rs10865710, rs1805192, and rs4684847 in PPARγ. Therefore, our presented study indicated that PPARα/γ polymorphisms should be involved in the regulation of plasma Lp(a) in independently and/or in an interactive manner, suggesting that PPARα/γ gene may influence the risk of hypertension, cardiovascular diseases, and dyslipidemia by regulating Lp(a) level.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 30:1709–1713

  2. Azhar S (2010) Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol 6:657–691

  3. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR (1998) Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47:1806–1808

  4. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470–477

  5. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M, Consortium P (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361:2518–2528

  6. Consilvio C, Vincent AM, Feldman EL (2004) Neuroinflammation, COX-2, and ALS—a dual role? Exp Neurol 187:1–10

  7. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082–1085

  8. Ding Y, Guo ZR, Wu M, Chen Q, Yu H, Luo WS (2012) Gene-gene interaction between PPARdelta and PPARgamma is associated with abdominal obesity in a Chinese population. J Genet Genomics 39:625–631

  9. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE (2000) Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43:673–680

  10. Frederiksen L, Brodbaek K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA (2002) Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87:3989–3992

  11. Gu SJ, Liu MM, Guo ZR, Wu M, Chen Q, Zhou ZY, Zhang LJ, Luo WS (2013) Gene-gene interactions among PPARalpha/delta/gamma polymorphisms for hypertriglyceridemia in Chinese Han population. Gene 515:272–276

  12. Hu XS, Guo ZR, Zhou H, Shi ZM, Wu M, Zhang J, Sun GX, Zhou ZY, Pan XQ, Yao CL (2006) Study on the prevalence of metabolic syndrome among 35–74 year-olds in Jiangsu province. Zhonghua Liu Xing Bing Xue Za Zhi 27:751–756

  13. Liu MM, Gu SJ, Guo ZR, Wu M, Chen Q, Zhou ZY, Yu H, Ding Y, Luo WS (2012) Association and interaction of peroxisome proliferator-activated receptor alpha with low high-density lipoprotein hyperlipidemia and with peroxisome proliferator-activated receptor gamma. Zhonghua Liu Xing Bing Xue Za Zhi 33:1218–1223

  14. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, Li MD (2007) A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 80:1125–1137

  15. Luo W, Guo Z, Wu M, Hao C, Hu X, Zhou Z, Zhou Z, Yao X, Zhang L, Liu J (2013) Association of peroxisome proliferator-activated receptor alpha/delta/gamma with obesity, and gene–gene interaction, in the Chinese Han population. J Epidemiol 23:187–194

  16. Matthews KA, Sowers MF, Derby CA, Stein E, Miracle-McMahill H, Crawford SL, Pasternak RC (2005) Ethnic differences in cardiovascular risk factor burden among middle-aged women: study of Women’s Health Across the Nation (SWAN). Am Heart J 149:1066–1073

  17. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, European Atherosclerosis Society Consensus P (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853

  18. Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, Gaudet D, Vohl MC (2004) Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 49:482–489

  19. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613–2618

  20. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM (2002) Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 22:805–810

  21. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres JP, Morgan K, Hudson TJ (2000) Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945–952

  22. Wassef N, Sidhom G, el Zakareya K, el Mohamed K (1997) Lipoprotein(a) in android obesity and NIDDM. Diabetes Care 20:1693–1696

Download references


This study was supported by Grants from the Scientific Research Fund of the National Ministry of Health (WKJ 2004-2-014) and the Priority Academic Program Development of Jiangsu Higher Education Institutions. The authors would like to thank all staff and all participants who contributed to PMMJS.

Author information

Correspondence to Chen Dong or Zhi-Rong Guo.

Additional information

Communicated by S. Hohmann.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 52 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xie, H., Hai, B., Wu, M. et al. Analysis on the association between PPARα/γ polymorphisms and lipoprotein(a) in a Chinese Han population. Mol Genet Genomics 289, 981–987 (2014). https://doi.org/10.1007/s00438-014-0866-9

Download citation


  • Lipoprotein(a)
  • PPARs gene
  • Polymorphism
  • Gene–gene interaction